Metformin May Reduce Prostate Cancer Recurrence Risk
Metformin may decrease the risk of biochemical recurrence (BCR) among men treated for prostate cancer (PCa), according to a recent systematic review and meta-analysis. Read the article.
Increased Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer.
Androgen deprivation therapy (ADT) may increase diabetes risk. As benefits of primary ADT (PADT) for localized PCa are controversial, and most PCa survivors are of advanced age with comorbidities, it is important to determine if PADT increases diabetes risk and what are the susceptibility factors. Read the article. (Free UroToday login required.)